Retisert for Wet Age-Related Macular Degeneration

Phase 2

Waitlist Available

Research Sponsored by Control Delivery Systems

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing if Retisert can help treat age-related macular degeneration.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Control Delivery SystemsLead Sponsor

Bausch & Lomb IncorporatedIndustry Sponsor

251 Previous Clinical Trials

57,415 Total Patients Enrolled

Media Library

Retisert (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT00032396 — Phase 2

Age-Related Macular Degeneration Research Study Groups:

Age-Related Macular Degeneration Clinical Trial 2023: Retisert Highlights & Side Effects. Trial Name: NCT00032396 — Phase 2

Retisert (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00032396 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial include individuals aged over thirty?

"This trial requires that participants are at least 55 years old, with no upper limit for enrollment."

Answered by AI

Are there any vacancies for prospective participants in this experiment?

"Clinicaltrials.gov reveals that this medical experiment is no longer seeking participants; it was initially posted on November 1st 2001 and last updated on May 25th 2006. However, there are currently 159 other trials searching for volunteers."

Answered by AI

What safety measures are being taken to protect those receiving this therapy?

"The safety of this experimental treatment has been rated a 2, as it is currently in Phase 2 clinical trials. Thus far, there have only been studies that demonstrate its security rather than efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

2001. "A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00032396.